

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

28 August 2015

Constellation Healthcare Technologies, Inc.
("Constellation" or "the Company")

Constellation shares to be traded on CREST

Constellation Healthcare Technologies, Inc., the US-based healthcare services and technology Company, announces that it has introduced a Depository Interest programme with Capita IRG Trustees Limited ("Capita") to enable its ordinary shares to be traded in CREST.

At the time of Admission of Constellation's Ordinary Shares to trading on AIM on 8 December 2014, restrictions on transfer under the United States securities laws required that its shares had to be held in certificated form for a period of at least 12 months following Admission. As a consequence of Regulation (EU) No. 909/2014 of the European Parliament and of the Council of 23 July 2014 on improving securities settlement in the European Union and on central securities depositories all shares traded on AIM have to be capable of electronic settlement as of 1 September 2015. In order to meet this requirement Constellation will be introducing a Depository Interest programme.

The Depository Interest programme will be effective from 1 September 2015. Under this programme Capita will issue Depository Interests to qualifying shareholders on a one-for-one basis for each qualifying security in the Company held by that qualifying shareholder. Capita will appear on the register of members of the Company as the shareholder but the beneficial interest and all rights in the relevant ordinary shares will remain with the original shareholder. The benefit of dematerialisation is that the Depository Interest can be held and transferred through CREST, thereby enhancing the liquidity of the Company's securities.

The Depository Interests will be traded on the existing line of stock and as such the Company's ISIN and TIDM will remain unchanged (USU210051004 and CHT respectively).

Further information explaining the process of dematerialising shares into Depository Interests will be available on the Company's website at www.constellationhealthgroup.com.

Enquiries:

Constellation Healthcare Technologies
Paul Parmar, Chief Executive Officer
Sam Zaharis, Chief Financial Officer

c/o Redleaf Communications
+44 (0)20 7382 4730

finnCap - Nominated Adviser and Joint Broker
Julian Blunt / Scott Mathieson

+44 (0)20 7220 0500

Stifel – Joint Broker

+44 (0)20 7710 7600

Jonathan Senior / Giles Balleny / Ben Maddison

Redleaf Communications - PR adviser
Charlie Geller / Harriet Lynch

+44 (0)20 7382 4730
constellation@redleafpr.com